Physician

Adam James Hanje, M.D.

According to 2025 Medicare claims, Adam Hanje, M.D. (NPI: 1043361298) practices gastroenterology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is OHIO GASTROENTEROLOGY GROUP, INC. (NPI: 1124197637; TIN: 31-0834038) and primary practice location at 43214-3908. Hanje is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Hanje's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 328 traditional Medicare patients, billed 818 HCPCS/CPT codes, and received $61,778 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,254 prescription claims across 316 beneficiaries totaling $2,864,318 in drug costs, led by Epclusa (Sofosbuvir/Velpatasvir). 2022 DME data shows 37 claims. Open Payments data shows 2 records totaling $3,303. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $65,616 and ending at $61,778. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $2,212,770 and ending at $2,864,318. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	298	702	$65,616
2016	385	1,012	$86,830
2017	342	838	$67,383
2018	378	1,012	$85,528
2019	422	1,139	$99,472
2020	367	842	$72,449
2021	344	768	$64,167
2022	308	790	$69,656
2023	304	550	$49,693
2024	328	818	$61,778

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	133	982	$2,212,770
2016	146	1,152	$1,726,759
2017	132	1,087	$749,278
2018	142	1,116	$1,144,770
2019	164	1,248	$1,263,963
2020	189	1,247	$1,273,424
2021	169	1,162	$870,125
2022	178	671	$474,913
2023	185	798	$1,689,335
2024	316	1,254	$2,864,318

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	119	$11,820
2016	N/R	106	$12,811
2017	27	287	$64,914
2018	11	319	$128,548
2019	12	208	$68,282
2020	37	257	$22,688
2021	59	430	$29,180
2022	N/R	37	$1,222
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	43	50	$114
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	44	47	$99
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	63	186	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	85	110	$87
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	121	152	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Epclusa	Sofosbuvir/Velpatasvir	74	2,072	$1,818,638
Xifaxan	Rifaximin	118	3,595	$379,194
Ocaliva	Obeticholic Acid	15	450	$132,338
Sofosbuvir-Velpatasvir	Sofosbuvir/Velpatasvir	16	448	$132,203
Rezdiffra	Resmetirom	21	630	$81,457

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$3,303	Madrigal Pharmaceuticals
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam James Hanje, M.D.?

Tedicare shows public-source Medicare data for Adam James Hanje, M.D. (NPI 1043361298), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam James Hanje, M.D. have ACO affiliation data?

Adam James Hanje, M.D. is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Adam James Hanje, M.D.?

Adam James Hanje, M.D. is linked to OHIO GASTROENTEROLOGY GROUP, INC. (billing NPI 1124197637) in the available physician profile data.

Does Adam James Hanje, M.D. have Open Payments data?

Adam James Hanje, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.